Bayer Completes Acquisition of Perfuse Therapeutics

Key Terms

intravitreal implant medical

A small medical device placed inside the eye that releases a drug slowly over weeks to months to treat retinal diseases; think of it as a timed-release patch delivered directly where the medicine is needed. Investors care because these implants can change how often patients need treatment, drive steady revenue streams, carry regulatory and patent value, and affect costs and clinical outcomes in ophthalmology markets.

endothelin receptor antagonist medical

An endothelin receptor antagonist is a type of drug that blocks the action of endothelin, a naturally occurring molecule that tightens blood vessels; think of it as turning down a volume knob that otherwise makes vessels constrict. Investors care because these drugs can treat serious conditions driven by vessel constriction (affecting demand, pricing and patient outcomes), and clinical trial results, safety profiles and regulatory approvals directly affect a company’s revenue prospects and valuation.

ophthalmology medical

Ophthalmology is the branch of medicine that diagnoses, treats and prevents eye diseases and vision problems, ranging from routine exams to surgery. For investors, it matters because advances, approvals or setbacks in eye drugs, surgical tools, diagnostics or implants can change sales, regulatory risk and long-term demand—think of it as the medical ‘repair and upgrade’ market for a vital organ.

diabetic retinopathy medical

Diabetic retinopathy is an eye disease where prolonged high blood sugar damages the tiny blood vessels and nerve tissue at the back of the eye, leading to blurred vision or blindness if untreated. Investors track it because the condition affects a large, growing patient population and drives demand for screening tools, drugs, surgical devices and long-term care—think of it like damaged wiring in a camera that creates a market for repairs and upgrades.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BERLIN--(BUSINESS WIRE)-- Bayer today announced the completion of the acquisition of Perfuse Therapeutics, Inc. As a result, Perfuse Therapeutics will now be fully integrated into Bayer. As announced previously, Bayer now holds the full rights pertaining to PER-001 intravitreal implant, a first in class, sustained release small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR).

This acquisition strengthens Bayer’s pharmaceutical pipeline and strategically fits with Bayer’s strong footprint and expertise in ophthalmology.

Under the terms of the agreement, Bayer paid an upfront payment of USD 300 million. The transaction carries a total potential value of up to USD 2.45 billion, comprising of the upfront payment and additional success-based milestone payments.

For Bayer, BofA Securities acted as exclusive financial advisor and Baker McKenzie acted as legal counsel. For Perfuse, Centerview Partners LLC acted as exclusive financial advisor and Goodwin Procter LLP acted as legal counsel.

About Perfuse Therapeutics
Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260616791003/en/

Contact for media inquiries (U.S.)
Elaine Colon, phone +1-732-236-1587
Email: elaine.colon@bayer.com

Contact for media inquiries (Global):
Lisa Varrelmann, phone: +49 1746466492
Email: lisa.varrelmann@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/de/investoren/ir-team

Source: Bayer